Brief: Galmed Announces Approval Of Ind Application In China For Aramchol For The Treatment Of Nash & Fibrosis In The Global Phase 3 Armor Registrational Study
03/05/2021 13:38
May 3 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O :
* GALMED ANNOUNCES APPROVAL OF IND APPLICATION IN CHINA FOR
ARAMCHOL FOR THE TREATMENT OF NASH & FIBROSIS IN THE GLOBAL
PHASE 3 ARMOR REGISTRATIONAL STUDY
* GALMED PHARMACEUTICALS LTD - CHINA TO JOIN GALMED'S PHASE
3
ARMOR REGISTRATIONAL STUDY FOR TREATMENT OF NASH & FIBROSIS
* GALMED PHARMACEUTICALS - LOOK FORWARD TO RAPIDLY
INITIATING
ENROLLMENT IN CHINA LATER IN H2 2021
Source text for Eikon: ID:nPn3rNs2ba
Further company coverage: GLMD.O
((Reuters.Briefs@thomsonreuters.com;))